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Subclinical hypothyroidism (SCH) has been studied since 2011 in regard to its effect on 
infertility. It is recommended that those who have been diagnosed with SCH before and during 
pregnancy have a TSH level <2.5 mIU/L. This achievement is best reached by using the 
supplementation of levothyroxine (LT4, T4). It is known that thyroid dysfunction in infertility 
exists. Abnormal thyroid levels have been hypothesized to have a pathophysiologic effect on 
oocytes and other reproductive cycles, which can correlate to infertility. Thyroid autoimmunity 
plays a role in the development of SCH. Thyroid autoimmunity in pregnancy can trigger SCH 
which would lead to adverse obstetrical outcomes. This review was based on a case study of a 
32-year-old female, in the postpartum period, with newly diagnosed hypothyroidism. In addition 
to this case study, phis particular literature search will discuss SCH and infertility with screening 
and treatment recommendations. Clinical relevance to this issue will reveal evidenced-based 
information on how to best screen and treat individuals with SCH and possible infertility and 
obstetrical outcomes.   
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Thyroid dysfunction is a common finding in women of reproductive age. The burden of 
thyroid disease affecting women before, during, or after pregnancy is substantial. 
Hypothyroidism is a clinical and metabolic state resulting in decreasing levels of free thyroid or 
resistance to hormone action. Hypothyroidism left untreated can lead to reproductive health 
problems which include infertility, miscarriage, and adverse obstetric and fetal outcomes 
(American Society for Reproductive Medicine, 2015). Thyroid Autoimmunity (TAI), which is 
the presence of autoantibodies, is the most common cause of hypothyroidism in women of the 
reproductive age (Rao, Zeng, Zhao, & Tang, 2018). Subclinical Hypothyroidism (SCH) is 
represented by an elevated TSH but a normal free T4 (Rao et al., 2018). There is now evidence 
that inadequate treatment of SCH can also lead to infertility, miscarriage, and other adverse 
obstetrical and neonatal neurodevelopment outcomes (American Society for Reproductive 
Medicine, 2015). Guidelines for management of these disorders during pregnancy were 
published in 2011 by the American Thyroid Association (ATA) with significant clinical and 
scientific advances established and updated as of 2017 (Alexander, Pearce, Brent, Brown et al., 
2017).  
Patients who are clinically hypothyroid warrant thyroid hormone replacement. 
Administration of synthetic thyroid hormones, levothyroxine (T4, LT4), liothyronine (T3), and 
liotrix (T4/T3) produce the same effects on the body’s tissues as one’s own thyroid hormones 
(Woo & Robinson, 2016). Woo and Robinson (2016) identify these medications are all 
pregnancy category A, which indicates they are safe for use in pregnancy. Levothyroxine is used 
most frequently to prevent over treating the patient and the overarching goals of treatment are to 
normalize thyroid levels with minimal adverse effects (Woo & Robinson, 2016). Untreated SCH 
during pregnancy increases risk and incidence of maternal hypertension, pre-eclampsia, 
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postpartum hemorrhage, ventricular dysfunction, spontaneous abortion, fetal death, or still born 
(Woo & Robinson, 2016). Rao et al., (2018) suggest even mild asymptomatic SCH may have 
adverse effects on cognitive function of offspring.  
After a thorough review, there is not enough evidence to recommend for or against 
screening for thyroid dysfunction in preconception or early pregnancy in patients with no known 
history of thyroid disease and asymptomatic (Maraka, Singh Ospina, Mastorakos, & O'Keeffe, 
2018). However, when indicated upon clinical signs and symptoms and possible infertility issues 
a screening may be necessary. The purpose of this report is to address thyroid dysfunction, 
explicitly addressing SCH, effects on infertility and obstetric outcomes, and recommendations on 
screening and treatment.  
Case report 
This case is on a 32-year-old female, LJ, who presents to primary care with concerns of 
increasing fatigue, feeling cool, abnormally dry skin, recent weight gain, irregular periods with 
heavy menstruation, and constipation. These symptoms were first noticed in October just after 
her last child was born. She shares, “The only thing that makes her feel warm is going to the club 
to sit in the hot tub.” LJ has been applying Jergens lotion twice daily and after showers to help 
with the dry skin. She reports 6-7 hours of sleep per night and has increased her caffeinated 
coffee intake to more than a pot of coffee a day. She is no longer breast feeding as her job is too 
time consuming. LJ has not noticed a change in her appetite and reports being too busy to 
exercise. She denies alcohol, tobacco, and illicit drug use. LJ reports no known allergies to 
medications and takes one pre-natal vitamin daily and a probiotic. A history of hypertension, 
which she is no longer being treated for, is shared but she is otherwise healthy. She has had three 
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successful and uncomplicated cesarean sections, the most recent being 11 months ago. LJ has a 
known family history of thyroid problems, diabetes mellitus, cancer, and heart disease. She is 
happily married to a husband who is supportive and together they have three children. She works 
full-time as a security secretary, Monday-Friday, 8:00am-5:00pm.  
A 10-point review of systems is completed, and the physical exam reveals the following 
pertinent positives: Vital signs are reviewed, the reported blood pressure is 130/80, which is 
increased by 14 mmHg systolic and 10 mmHg diastolic. Movement is rather slow with dull 
facies and fatigued appearance. Thickened tongue is evidenced by teeth indentations on the 
lateral edges. Excessively dry cool skin is noted on bilateral upper extremities. Thyroid is 
palpable. Bowel sounds are hypoactive. Deep tendon reflexes on patellar and biceps appear 
hyporeflexic. Diagnostics include the following non-fasting labs: CBC (within normal limits), 
BMP (within normal limits), serum betaHCG (negative), and TSH (elevated 6.160 mIU/L). 
Previous lab results prior to pregnancy were all within normal limits, including a TSH.  
LJ’s presentation, clinical manifestations, and diagnostics are pertinent for postpartum 
thyroiditis, indicating hypothyroidism. Discussion was held regarding cause of hypothyroidism. 
Counselling was completed on Levothyroxine use and importance of taking it on an empty 
stomach and without other medications. LJ will proceed by taking 25 mcg of levothyroxine daily 
and recheck a TSH in 4-6 weeks. Constipation is discussed with the patient that this is most 
likely due to her hypothyroidism. However, I did encourage exercise, increase water intake, and 
the use of MiraLAX once a day until her stools are of normal consistency. Education was 
completed on dry skin being consistent with hypothyroidism. I encouraged the use of Vanicream 
BID and after showers. In addition, 1,000 mg of Fish Oil PO daily. LJ was appreciative of the 
homeopathic suggestions. 
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Literature review  
Methods 
A systematic literature search was performed using a combination of the following key 
words: Subclinical hypothyroidism, infertility, hypothyroidism, miscarriage, pregnancy, 
complication, elevated TSH, birth defect, and thyroid dysfunction. The search was restricted to 
CINAHL and PubMED through the University of North Dakota Harley French Library. Practical 
screening was completed, and inclusion criteria included the following: publication dates from 
2011 through 2018, controlled vocabulary terms as above, and full text articles from educational 
journals. Content included any SCH, TAI, and some hypothyroidism and effects on reproduction. 
This search yielded 382 studies, with 12 full text articles were screened. 2 studies were excluded 
due to being out of date rage, resulting in 10 eligible studies were included in this synthesis. One 
animal study was included because of the yield that could be true in future human studies. The 
quality of evidence is high including systematic reviews and randomized control studies (RCT). 
The following literature review will deviate mildly from the case study presented to focus on 
SCH and reproductive problems.  
Concept 1: Screening 
Screening is defined as a systematic search for a health condition testing otherwise 
healthy people (Alexander et al., 2017). Screening for thyroid dysfunction is a controversial 
topic. Routine screening women at risk of conception along with optimization of their thyroid 
status could result, as many studies like Alexander et al., (2017) has shown, in significant health 
benefits for their offspring and their obstetrical progress. Alexander et al., (2017), also suggests, 
that regardless if it is before conception or during pregnancy, due to the potential dangers of the 
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SCH on the fetus, universal screening to evaluate thyroid function should be done in all women. 
ATA argues that this is an inexpensive way to attempt control of SCH risks pre-conception 
because levothyroxine is an inexpensive drug. According to the American Endocrine Society 
(AES), based on the potential benefits of early detection and treatment of SCH, routine screening 
is recommended for SCH in adults including pregnant women and those who want to become 
pregnant, as it significantly outweighs the risks (Maheshwari, Bhide, Pundir, & Bhattacharya, 
2017).  
In opposition, this could also be an expensive route, cause increased anxiety, frequent 
monitoring for euthyroid, unneeded drug use, and potential harm. In a systematic review, by 
Maheshwari et al., (2017), administration of thyroxine during pregnancy has failed to 
demonstrate appreciable health benefits in those with a TSH <4 mIU/L. Thyroid function during 
pregnancy is difficult to manage and interpret compared to nonpregnant patients, because of 
altering anatomy of the thyroid during pregnancy along with age (Alexander et al., 2017). 
Therefore, optimization of TSH pre-conception should be practiced. Ideal pre-conception TSH 
should be <2.5 mIU/L, which will generate an inevitable increase in numbers of pre-conception 
women who will need treatment and monitoring (Alexander et al., 2017). ATA, American 
College of Obstetrics and Gynecology (ACOG), and Royal College of Obstetrician and 
Gynecologists (RCOG) suggest routine pre-conception testing for all is not recommended 
because of limited data from large scale randomized trials in the general population (Maheshwari 
et al., 2017). To date, studies evaluating this continue to demonstrate mixed conclusions on 
screening. The gap in this concept includes the unexpected pregnancies and lifelong follow-up 
compliance.  
Concept 2: Treatment 
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There is controversy regarding treatment of SCH in the infertile female patient because of 
the risks and benefits (American Society for Reproductive Medicine, 2015). The mechanism for 
the T4 treatment for fertility has not been clarified in detail. It is suggested it may have an effect 
on the hypothalamus-pituitary-gonadal axis and menstrual abnormalities, anovulation, and 
hyperprolactinaemia (Yoshioka, Waka, Amino, Nobuyuki et al., 2015). Levothyroxine is rated 
category A, safe in pregnancy (Woo & Robinson, 2016). Evidence suggests that a TSH > 4 
mIU/L during pregnancy is associated with miscarriage (American Society for Reproductive 
Medicine, 2015). There is good evidence that levothyroxine treatment in pregnant women with 
SCH with TSH levels >4 mIU/L had improved pregnancies and miscarriage rates (American 
Society for Reproductive Medicine, 2015). Infertile women with SCH, per the guidelines of the 
AES, American Association of Clinical Endocrinologists (AACE), and ATA support use of 
levothyroxine if offspring are wanted (Yoshioka et al., 2015). Treatment with low dose LT4 
should be started if SCH is diagnosed; levels should be <2.5 mUI/L to be therapeutic and low 
risk during pregnancy (Yoshioka et al., 2015). There is a very high success rate in pregnancies 
and shorter infertility periods for those patients who had SCH and were treated with 
levothyroxine, showing that T4 enhanced fertility in those who were infertile (Yoshioka et al., 
2015). If SCH is untreated, there is good evidence that SCH diagnosed in pregnancy is 
associated with adverse neurodevelopmental outcomes (American Society for Reproductive 
Medicine, 2015).  
In SCH female populations undergoing invitro fertilization (IVF), despite T4 treatment, 
less implantation and less live birth rates occurred than in euthyroid women (Yoshioka et al., 
2015). In contrast, Yoshioka et al., (2015) although recognizing that T4 therapy was doubtful in 
other reports, found that clinical pregnancies were significantly higher in treated infertile patients 
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with SCH who participate in IVF than those not receiving treatment. Yoshioka et al., (2015) 
suggests that TSH may predict fertilization in IVF and reflect the importance of thyroid 
hormones in oocyte physiology. It can stimulate oocytes directly to improve embryo quality in 
IVF (Yoshioka et al., 2015). Limitations exist in the type of studies performed including the need 
for more RCT involving infertile patients and effectiveness of T4 treatment.  
Concept 3: Infertility 
SCH is more prevalent in infertile women and highest among those with ovulatory 
dysfunction. Thyroid autoimmunity (TAI) is one of the most important issues regarding the care 
of infertile pregnant women (Oiwa, Minemura, Nishio, Yamazaki, & Komatsu, 2019). Thyroid 
autoimmunity is defined by Wang, Haining, Gao, Hongwei et al., (2017), as a presence of 
thyroid autoantibodies, which is the most common cause for miscarriages in infertile women and 
also associated with pregnancy complications. Women who have normal TSH levels but test 
positive for thyroid antibodies are at 2-3-fold higher risk for miscarriage than those who are not 
positive for antibodies (Wang et al., 2017). It is suggested that those with thyroid autoimmunity 
are predisposed to develop SCH or overt hypothyroidism because pregnancy can trigger this 
progression (Wang et al., 2017). T4 treatment does have a potential to reduce miscarriage rate, so 
supplementation is recommended for women who have TAI who are undergoing IVF (Rao et al., 
2018). In opposition, ATA and AES declare there is insufficient evidence and lack of RCT to 
recommend for or against treating women with normal TSH but positive antibodies and recurrent 
miscarriages (Wang et al., 2017). The small studies described in Rao et al., (2018), observed no 
difference in miscarriage rates for women who underwent T4 treatment for TAI. LT4 should be 
reconsidered when making decisions about treatment based on TSH for those who have thyroid 
autoimmunity based on risks and benefits. Data assessing effect of SCH on fertility is limited due 
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to the variations of SCH and lack of adequate control groups with TAI (American Society for 
Reproductive Medicine, 2015)  
Concept 4: Obstetric Outcomes 
SCH during pregnancy, with a TSH outside of normal range, is associated with adverse 
obstetric outcomes. SCH and pregnancy has long been studied. Of all obstetrical problems, 
miscarriage was the most significant of adverse pregnancy outcomes in those with SCH (Rao et 
al., 2018). Pre-eclampsia, perinatal mortality, and recurrent miscarriages were also noted (Van 
Den Boogaard et al., 2011). Van Den Boogaard et al., (2011), did show the relation between 
SCH and pre-eclampsia. It is also noted the literature found in Van Den Boogaard’s et al., (2011) 
study is outdated, but it is essentially one of the first studies on thyroid and infertility, which is 
why it is included. It is also interesting to note the hypotheses addressed in the study that have 
been evidenced-based to be true. Levothyroxine did not have an improvement on developmental 
outcomes with those diagnosed with SCH in pregnancy but did improve miscarriage rates 
(American Society for Reproductive Medicine, 2015). The RCT based meta-analysis by Rao et 
al., (2018), confirms the benefits of T4 supplementation to decrease risk of miscarriage. It was 
found not to improve live pregnancy rates, preterm birth, or rates of clinical pregnancy (Rao et 
al., 2018). Thyroid treatment in patients with thyroid disorders can only be justified if there is an 
association with the thyroid and obstetric outcomes demonstrated (Van Den Boogaard et al., 
2011). Limitations include more studies to help determine if LT4 replacement can improve long 
term complications in women with SCH.  
In summary, based on the potential benefits of early detection and treatment of SCH, 
routine screening is recommended for SCH in adults, including pregnant women and those who 
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want to become pregnant, as it significantly outweighs the risks (Alexander et al., 2017). SCH is 
more prevalent in infertile women and highest among those with ovulatory dysfunction (Oiwa et 
al., 2019). Thyroid autoimmunity is one of the most important issues regarding the care of 
infertile pregnant women. LT4 should be reconsidered when making decisions about treatment 
based on TSH for those who have thyroid autoimmunity (wang et al., 2017). There is a very high 
success rate in pregnancies and shorter infertility periods for those patients who had SCH and 
were treated with levothyroxine, showing that T4 enhanced fertility in those who were infertile 
(Yoshioka et al., 2015). TSH may predict fertilization in IVF and reflect the importance of 
thyroid hormones in oocyte physiology; it can stimulate oocytes directly to improve embryo 
quality in IVF (Yoshioka et al., 2015). Levothyroxine did not have an improvement on 
developmental outcomes with those diagnosed with SCH in pregnancy but did improve 
miscarriage rates when pregnant (American Society for Reproductive Medicine, 2015). Overall, 
more controlled studies will need to be done on each of the concepts above along with the 
pathophysiologic studies in regard to what abnormal TSH levels or positive thyroid antibodies 





• Based on the potential benefits of early detection and treatment of SCH, routine screening 
is recommended for SCH in adults including pregnant women (Alexander et al., 2017). 
Mixed conclusions exist because ATA, ACOG, and RCOG suggest routine pre-
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conception testing for all is not recommended because of limited data on from large scale 
randomized trials in the general population. 
• There is good evidence that levothyroxine treatment in pregnant women with SCH with 
TSH levels >4 mIU/L had improved pregnancies and miscarriage rates (Yoshioka et al., 
2015). There is a very high success rate in pregnancies and shorter infertility periods for 
those patients who had SCH and were treated with levothyroxine, showing that T4 
enhanced fertility in those who were infertile (Yoshioka et al., 2015). 
• TSH may predict fertilization in IVF and reflect the importance of thyroid hormones in 
oocyte physiology (Yoshioka et al., 2015). Clinical pregnancies were significantly higher 
in treated infertile patients with SCH who participate in IVF than those not receiving 
treatment (Rao et al., 2018). 
• Thyroid autoimmunity (TAI) is one of the most important issues regarding the care of 
infertile pregnant women. Women who have normal TSH levels but test positive for 
thyroid antibodies are at 2-3-fold higher risk for miscarriage and pregnancy can trigger 
this progression (Wang et al., 2017). T4 treatment does have a potential to reduce 
miscarriage rate, so supplementation is recommended for women who have TAI (Owia et 
al., 2019). However, there is insufficient evidence and lack of RCT to recommend for or 
against treating women with normal TSH but positive antibodies and recurrent 
miscarriages. 
• SCH during pregnancy with a TSH outside of normal range is associated with adverse 
obstetric outcomes. Levothyroxine did not have an improvement on developmental 
outcomes with those diagnosed with SCH in pregnancy but did improve miscarriage rates 
(American Society for Reproductive Medicine, 2015). Thyroid treatment in patients with 
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thyroid disorders can only be justified if there is an association with the thyroid and 
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